Online inquiry

IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13539MR)

This product GTTS-WQ13539MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MCAM gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_006500.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4162
UniProt ID P43121
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13539MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8638MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ14243MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ1973MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ10433MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ10313MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LJM716
GTTS-WQ1667MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ13418MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ15898MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XMT-1536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW